课题基金 / 基金详情

Molecular and Cellular Mechanisms of Host Defense

Molecular and Cellular Mechanisms of Host Defense
宿主防御的分子和细胞机制
批准号:
8080279
负责人:
Tse-Hua Tan
金额:
$19.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-05-01 至 2013-07-31

项目摘要

项目成果

Tse-Hua Tan的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):该培训计划旨在为年轻科学家在免疫学研究中的独立职业做好准备。在这一领域需要聪明的,受过全面训练的调查人员是巨大的:自身免疫性疾病,先天性和获得性免疫缺陷,淋巴肿瘤是当今最重要和最令人困惑的发病原因之一。在宿主防御的细胞和分子机制水平上的研究对于阐明和预防骨髓和实体器官移植的免疫并发症以及对基因治疗的免疫应答也至关重要。实习生(博士前和博士后(M.D.或博士学位)贝勒医学院免疫学系的17名主要或联合任命的项目教师之一指导,其研究项目涉及现代免疫学的各个领域,包括淋巴细胞活化和凋亡,淋巴细胞分化,免疫反应,炎症,HIV,基因治疗,造血干细胞生物学,粘附分子和细胞因子。受训人员:需要为三名博士前和三名博士后受训人员提供支助。博士前培训生主要从已进入免疫学研究生课程的学生中选择,并选择一名培训教师作为他们的论文导师。通过其他课程进入参与教师实验室的学生也可以考虑。这些受训人员完成免疫学基础和高级领域以及现代细胞和分子生物学的核心课程。博士后培训生从高素质的博士生中选拔。或者医学博士申请人到个别培训学院或通过广告寻找。除了研究培训和职业发展的教师指导外,博士后学员还可以参加高级免疫学课程。训练设施与环境:免疫学系有35名教师。十个小学教师中的九个位于大约23,000平方英尺的连续空间中,其中包括Alkek研究生研究中心的12,300平方英尺。总的来说,培训教师带来了超过1700万美元的年度直接补助金成本,并占据了约41,000平方英尺的实验室空间,包括免疫学系和贝勒中心综合大楼的现代研究设施以及休斯顿VA,德克萨斯州儿童和卫理公会医院。目前有29名博士预科生在部门和45名博士后研究员在该计划教师的实验室。培训在贝勒医学院的研究环境中进行,贝勒医学院在全球医学院中排名靠前,是NIH资助的领导者。德克萨斯医疗中心是世界上最大的医疗中心,提供了一个高度互动的培训环境,合作丰富。
英文摘要
DESCRIPTION (provided by applicant): This training program is designed to prepare young scientists for independent careers in immunological research. The need for bright, thoroughly trained investigators in this area is great: diseases of autoimmunity, congenital and acquired immunodeficiency, and lymphoid neoplasms are among the most significant and perplexing causes of morbidity today. Research at the level of cellular and molecular mechanisms of host defense is also critical for elucidating and preventing the immunologic complications of bone marrow and solid organ transplantation and immune responses to gene therapy. Trainees (predoctoral and postdoctoral (M.D. or Ph.D.) fellows) are mentored by one of 17 program faculty with primary or joint appointments in the Department of Immunology at Baylor College of Medicine, whose research programs address diverse areas of modern immunology, including lymphocyte activation and apoptosis, lymphocyte differentiation, immune responses, inflammation, HIV, gene therapy, hematopoeitic stem cell biology, adhesion molecules, and cyotokines. Trainees: Support for three predoctoral and three postdoctoral trainees is requested. Predoctoral trainees are selected primarily from among students who have matriculated into the Immunology graduate program and chosen one of the training faculty as their thesis mentor. Students who have entered the laboratories of participating faculty through other programs may also be considered. These trainees complete a core curriculum in basic and advanced areas of immunology and in modern cell and molecular biology. Postdoctoral trainees are selected from highly qualified Ph.D. or M.D. applicants to individual training faculty or sought through advertisements. In addition to faculty guidance of research training and career development, postdoctoral trainees may take advanced immunology courses. Training Facilities and Environment: There are 35 faculty in the Department of Immunology. Nine of the ten primary faculty are housed in approximately 23,000 square feet of contiguous space, including 12,300 square feet in the Alkek Center for Graduate Research. Collectively, the training faculty bring in over $17.0 million in annual direct grant costs and occupy approximately 41,000 square feet of laboratory space, including the Department of Immunology and modern research facilities in the central Baylor complex and the Houston VA, Texas Children's, and Methodist hospitals. Currently there are 29 predoctoral students in the Department and 45 postdoctoral fellows in the program faculty's laboratories. Training occurs in the research environment of Baylor College of Medicine, highly ranked among medical schools worldwide and a leader in NIH funding. The Texas Medical Center is the largest medical center in the world, and provides a highly interactive training environment rich in collaborations.
期刊论文(41)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1158/0008-5472.can-09-1507
发表时间: 2009-10-15
期刊: Cancer research
影响因子: 11.2
作者: [Hong B, Ren W, Song XT, Evel-Kabler K, Chen SY, Huang XF]
通讯作者: Huang XF
DOI: --
发表时间: 2003-10
期刊: Cancer research
影响因子: 11.2
作者: [K. Freeman;R. Gangula;B. Welm;M. Ozen;B. Foster;J. Rosen;M. Ittmann;N. Greenberg;D. Spencer]
通讯作者: K. Freeman;R. Gangula;B. Welm;M. Ozen;B. Foster;J. Rosen;M. Ittmann;N. Greenberg;D. Spencer
Association of 2',5'-oligoadenylate synthetase with the prolactin (PRL) receptor: alteration in PRL-inducible stat1 (signal transducer and activator of transcription 1) signaling to the IRF-1 (interferon-regulatory factor 1) promoter.
2,5-寡腺苷酸合成酶与催乳素 (PRL) 受体的关联:PRL 诱导型 stat1(信号转导器和转录激活剂 1)向 IRF-1(干扰素调节因子 1)启动子信号传导的改变。
DOI: 10.1210/mend.14.2.0421
发表时间: 2000
期刊: Molecular endocrinology (Baltimore, Md.)
影响因子: --
作者: [McAveney,KM, Book,ML, Ling,P, Chebath,J, Yu-Lee,L]
通讯作者: Yu-Lee,L
DOI: 10.1002/stem.606
发表时间: 2011-04
期刊: STEM CELLS
影响因子: 5.2
作者: [Shahi, Payam, Seethammagari, Mamatha R., Valdez, Joseph M., Xin, Li, Spencer, David M.]
通讯作者: Spencer, David M.
共 12 条
    Protein Phosphatases in Lymphocyte Signal Transduction
    • 批准号:
      6964971
    • 项目类别:
    • 资助金额:
      $31.88万
    • 财政年份:
      2005
    • 负责人:
      Tse-Hua Tan
    • 依托单位:
    Protein Phosphatases in Lymphocyte Signal Transduction
    • 批准号:
      7082143
    • 项目类别:
    • 资助金额:
      $36.62万
    • 财政年份:
      2005
    • 负责人:
      Tse-Hua Tan
    • 依托单位:
    PP4 and IGF-1 Signaling in Breast Tumorigenesis
    • 批准号:
      6864953
    • 项目类别:
    • 资助金额:
      $12.9万
    • 财政年份:
      2005
    • 负责人:
      Tse-Hua Tan
    • 依托单位:
    Protein Phosphatases in Lymphocyte Signal Transduction
    • 批准号:
      7614172
    • 项目类别:
    • 资助金额:
      $34.88万
    • 财政年份:
      2005
    • 负责人:
      Tse-Hua Tan
    • 依托单位:
    国内基金
    海外基金
    Kidney injury molecular(KIM-1)介导肾小管上皮细胞自噬在糖尿病肾病肾间质纤维化中的作用
    • 批准号:
      81300605
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      23.0万元
    • 批准年份:
      2013
    • 负责人:
      唐琳
    • 依托单位:
    Molecular Plant
    Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
    Molecular Plant